Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

Kylie Keijzer, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Gerwin A. Huls, Lisanne V. van Dijk, Tom van Meerten, Anne G.H. Niezink

Blood (2023) 142 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2023-173947

Published: 2023

Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Blood (2023) 142 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2023-173873

Published: 2023

Journal Articles

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

Hilde T Van Der Galien, Hilde AM Kooistra, Robby Kibbelaar, Nic JGM Veeger, Marcel Nijland, Geert A. Huls, Tom Van Meerten, Rozemarijn S Van Rijn

Blood (2023) 142 (Supplement 1): 444.

https://doi.org/10.1182/blood-2023-185993

Published: 2023

Journal Articles

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Blood (2022) 140 (Supplement 1): 1957–1959.

https://doi.org/10.1182/blood-2022-169164

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Blood (2022) 140 (Supplement 1): 10399–10401.

https://doi.org/10.1182/blood-2022-156117

Published: 2022

Journal Articles

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 8347–8349.

https://doi.org/10.1182/blood-2022-168991

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy

Anne Niezink, Jaap van Doesum, Max Beijert, Marcel Nijland, Hans Langendijk, Dianne Busz, Anne P.G. Crijns, Gerwin A. Huls, Tom Van Meerten

Blood (2021) 138 (Supplement 1): 2510.

https://doi.org/10.1182/blood-2021-151404

Published: 2021

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Blood (2021) 138 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2021-147403

Published: 2021

Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2.

https://doi.org/10.1182/blood-2021-148039

Published: 2021

Journal Articles

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Sabine Haggenburg, Birgit I. Lissenberg-Witte, Robert S. Van Binnendijk, Gerco Den Hartog, Bhoekhan S. Michel, Nienke J.E. Haverkate, Dennis M. De Rooij, Annoek E.C. Broers, Pim G.N.J. Mutsaers, Tom Van Meerten, Jaap van Doesum, Arnon P. Kater, Sonja Zweegman, Marit J. Van Gils, Bram Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof

Blood (2021) 138 (Supplement 1): 754.

https://doi.org/10.1182/blood-2021-150379

Published: 2021

Journal Articles

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, MBBS, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Hervé Finel, Irma Khvedelidze, Hannah Hunter, MB,FRCPath,MRCP, Xavier Poire, Bruno Lioure, MD, Karl S Peggs, Robin Foà, MD, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Tom Van Meerten, MD PhD, Juan Jose Bargay, Christoph Schmid, MD, Vergote Vibeke, Arnold Ganser, MD, Luca Castagna, MD, Ghulam J. Mufti, Silvia Montoto, MD

Blood (2019) 134 (Supplement_1): 701.

https://doi.org/10.1182/blood-2019-123442

Published: 2019

Journal Articles

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Max Topp, MD, Tom Van Meerten, MD PhD, Roch Houot, MD PhD, Monique C. Minnema, Noel Milpied, MD, Pieternella J. Lugtenburg, MD PhD, Catherine Thieblemont, MD PhD, Martin Wermke, MD, Kevin Song, MD, Irit Avivi, MD, John Kuruvilla, MD, Ulrich Dührsen, Prof, MD PhD, Rachel Chu, PhD, Lianqing Zheng, PhD, Vicki Plaks, PhD, Anne Kerber, MD, Marie Jose' Kersten, MD PhD

Blood (2019) 134 (Supplement_1): 243.

https://doi.org/10.1182/blood-2019-126081

Published: 2019

Journal Articles

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Tom Van Meerten, Renee Bouwstra, Bsc, Yuan He, PhD, de Boer Janneke, Bsc, Hilde Kooistra, MD PhD, Rudolf Fehrmann, MD PhD, Emanuele Ammatuna, MD PhD, Gerwin Huls, MD PhD, Edwin Bremer, PhD

Blood (2018) 132 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2018-99-114561

Published: 2018

Journal Articles

Excessively High-Affinity Single-Chain Fragment Variable Region in a Chimeric Antigen Receptor Can Counteract T-Cell Proliferation

Keisuke Watanabe, MD, Seitaro Terakura, MD PhD, Susumu Uchiyama, PhD, Anton C. Martens, PhD, Tom van Meerten, PhD, Hitoshi Kiyoi, MD PhD, Tetsuya Nishida, MD PhD, Tomoki Naoe, MDPhD, Makoto Murata, MD PhD

Blood (2014) 124 (21): 4799.

https://doi.org/10.1182/blood.V124.21.4799.4799

Published: 2014

Journal Articles

Development of an Effective Safety Switch for Selective Elimination of Human T Cells In Vivo after Adoptive Transfer.

Tom van Meerten, BSc, Henk Rozemuller, PhD, Wendy J.M. Mackus, PhD, Paul W.H.I. Parren, PhD, Jan G.J. van de Winkel, PhD, Marie-Jose Claessen, MSc, Rozemarijn S. van Rijn, MD, Anton Hagenbeek, MD PhD, Anton C.M. Martens, PhD, Saskia B. Ebeling, PhD

Blood (2006) 108 (11): 5488.

https://doi.org/10.1182/blood.V108.11.5488.5488

Published: 2006

Journal Articles

A New Human CD20 Antibody for Improved Killing of CD20-Transgenic T Cells for Allogeneic Stem Cell Transplantation.

Tom van Meerten, PhD, Wendy J.M. Mackus, PhD, Paul W.H.I. Parren, PhD, Jan G.J. van de Winkel, PhD, Anton Hagenbeek, MD, Saskia B. Ebeling, PhD

Blood (2005) 106 (11): 5538.

https://doi.org/10.1182/blood.V106.11.5538.5538

Published: 2005

Journal Articles

Complement-Induced Cell Death by Rituximab Depends on CD20-Expression Level and Acts Complementary to Antibody-Dependent Cell-Mediated Cytotoxicity.

Tom van Meerten, PhD, Rozemarijn S. van Rijn, MD, Anton Hagenbeek, Prof, MD, Saskia B. Ebeling, PhD

Blood (2005) 106 (11): 775.

https://doi.org/10.1182/blood.V106.11.775.775

Published: 2005

Journal Articles

High, Stable and Homogenous CD20 Expression for Efficient Rituximab-Induced Elimination of CD20+ Alloreactive Donor T Cells in the Novel CD20/Rituximab ‘Suicide’ System.

Tom van Meerten, Marie-Jose Claessen, Anton Hagenbeek, MD, Saskia Ebeling, PhD

Blood (2004) 104 (11): 1750.

https://doi.org/10.1182/blood.V104.11.1750.1750

Published: 2004

NARROW

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Excessively High-Affinity Single-Chain Fragment Variable Region in a Chimeric Antigen Receptor Can Counteract T-Cell Proliferation

Development of an Effective Safety Switch for Selective Elimination of Human T Cells In Vivo after Adoptive Transfer.

A New Human CD20 Antibody for Improved Killing of CD20-Transgenic T Cells for Allogeneic Stem Cell Transplantation.

Complement-Induced Cell Death by Rituximab Depends on CD20-Expression Level and Acts Complementary to Antibody-Dependent Cell-Mediated Cytotoxicity.

High, Stable and Homogenous CD20 Expression for Efficient Rituximab-Induced Elimination of CD20+ Alloreactive Donor T Cells in the Novel CD20/Rituximab ‘Suicide’ System.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only